Nijmegen/Amsterdam, January 10, 2017 Okklo Life Sciences B.V. and Sanquin sign commercialization agreement to enter IND enabling studies and clinical development. Okklo Life Sciences B.V. (Nijmegen, The Netherlands) and Sanquin Blood Supply Foundation (Amsterdam, the Netherlands) today announced that they have signed an agreement regarding the further development and commercialization of their first in …
Nijmegen/Amsterdam, May 14 2016 RedMedTech Ventures funding enables further development of cyclodextrines. Sanquin Blood Supply Foundation and Okklo Life Sciences BV extend their cardiovascular program. Okklo Life Sciences BV and Sanquin Blood Supply Foundation (Amsterdam) announced today that they are going to expand their research and licensing agreement. Funding from RedMedTech Ventures allows the …
Amsterdam/Oss, 20 November 2014 Sanquin Blood Supply, division Research and Okklo Life Sciences BV have entered into a research and licensing agreement for a collaborative project based on Okklo’s OCTOPlex technology. In this project, novel proprietary cyclodextrins (ring-shaped sugar molecules) will be evaluated pre-clinically for a number of (cardiovascular) indications. “We are very much …
October 2nd, 2014 Today BioAxis Research and Okklo Life Sciences have entered into an exclusive collaboration for R&D projects. Their OCTOPlex technology contributes to the rapid development of specific sugar molecules, cyclodextrins, as potential treatment for various diseases. BioAxis Research BV and Okklo Life Sciences BV have unique expertise on the design and development …
As of May 1st, Stepan Peters (Director Preclinical Development at Okklo) is appointed part-time professor at the Fontys University of Applied Sciences (Eindhoven, The Netherlands). The Dutch Universities of Applied Sciences (‘Hogeschool’) are an attractive partner for SMEs like Okklo Life Sciences, providing access to students (also as potential future employees), but also because of …
Dr Martin Feiters and Prof Dr Floris Rutjes (Institute for Molecules and Materials, Radboud University Nijmegen, the Netherlands) and Okklo Life Sciences (Oss, The Netherlands) receive a KIEM-grant for their project ‘Pervasive Cyclodextrins For Therapeutic Lipid Transfer’. In this project, a number of new cyclodextrins will be designed, synthesized and tested as potential medicines for …
In the Cyclon Hit FP7 ITN program (“Novel multifunctional cyclodextrin-based nanocarriers for drug-encapsulation and delivery as a strategy to overcome current therapeutic drawbacks”) there are a number of vacancies for (early stage) researchers, including a vacancy in Athens (Greece) as well as other vacancies in Italy, Spain and elsewhere. Deadlines are for application are approaching rapidly! …
Okklo Life Sciences partners with Dutch universities and SME Dr Jeroen Codee (Leiden Institute of Chemistry, Leiden), Prof Dr Hans Aerts (Medical Biochemistry, University of Amsterdam) and Dr Daniel Zollinger (Okklo Life Sciences, Oss) receive a KIEM-grant for their project ‘Designer cyclodextrins & sphingolipids involved in lysosomal storage disease’. In this project, which also involves …
internship chemistry R&D okklo life sciences is a biotech start-up company at the Pivot Park in Oss, The Netherlands, working on orphan and neglected diseases. Our platform technology: a targeted approach based on a chemical (cyclodextrin) platform. Our focus: expansion of our R&D collaboration network and projects. For our biCycle chemistry program, a collaboration …
okklo life sciences As a biotech start-up company at the Pivot Park in Oss, The Netherlands, Okklo Life Sciences is building a project portfolio in orphan and neglected diseases. Our platform technology: a targeted approach based on a chemical (cyclodextrin) platform. Apart from our on-going focus to expand our R&D collaboration network and expanding the number …